⌕
Zenas Biopharma · ZBIO · Nasdaq
Tenet 29 · Weak
Compare
$27.75−0.64%At closeTenet 29 · Weak
$27.75−0.18 (−0.64%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Zenas Biopharma (ZBIO) Institutional Ownership

13F filers reported holding 31.9% of Zenas Biopharma (ZBIO) shares as of Sep 30, 2026, across 76 filers.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice
Held by 13F filers
31.9%
Sep 30, 2026
13F filers
76
quarter ended Sep 30, 2026
13F value
$584.0M
21.6M shares
Quarter's fund flow
Mild accumulation
12 new · 4 closed

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

13F fund flowQuarter ended Sep 30, 2026: more funds added or entered than trimmed or exited, mild accumulation (12 new · 35 increased · 13 reduced · 4 closed · 12 unchanged or with no prior quarter on file). Flows at this scale move slowly; treat as context. These positions are 49 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
Basis: shares reported by 76 13F filers for Sep 30, 2026, over shares outstanding implied from the current quote, measured 49 days apart. It measures the ownership we have filings for, not total institutional ownership, and it moves with the share count between filings.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Sep 1, 2026Oliger Christy J.directorAcquired · Grant / award37,000Stock Option (Right to Buy)—↗
Jun 15, 2026Nunn Jason RaleighdirectorAcquired · Grant / award18,500Stock Option (Right to Buy)—↗
Jun 15, 2026Lu HongbodirectorAcquired · Grant / award18,500Stock Option (Right to Buy)—↗
Jun 15, 2026MOULDER LEON O JRSee RemarksAcquired · Grant / award500,000Stock Option (Right to Buy)—↗
Jun 15, 2026ORLOFF JOHN JdirectorAcquired · Grant / award18,500Stock Option (Right to Buy)—↗
Jun 15, 2026von Moltke LisaSee RemarksAcquired · Grant / award150,000Stock Option (Right to Buy)—↗
Jun 15, 2026Allen Patricia LdirectorAcquired · Grant / award18,500Stock Option (Right to Buy)—↗
Jun 15, 2026Boylan James PdirectorAcquired · Grant / award18,500Stock Option (Right to Buy)—↗
Jun 15, 2026ENRIGHT PATRICK GdirectorAcquired · Grant / award18,500Stock Option (Right to Buy)—↗
Jun 15, 2026Farmer Joseph LSee RemarksAcquired · Grant / award175,000Stock Option (Right to Buy)—↗
Jun 15, 2026Fox Jennifer A.See RemarksAcquired · Grant / award125,000Stock Option (Right to Buy)—↗
May 18, 2026MOULDER LEON O JRChief Executive OfficerAcquired · Open-market buy60,000$16.88↗
Apr 29, 2026MOULDER LEON O JRChief Executive OfficerAcquired · Open-market buy35,000$17.62↗
Apr 28, 2026MOULDER LEON O JRChief Executive OfficerAcquired · Open-market buy25,000$18.02↗
Mar 31, 2026Lu HongbodirectorAcquired · Open-market buy3,768$18.63↗
Mar 31, 2026Fairmount Funds Management LLCdirectorAcquired · Open-market buy150,000$20.00↗
Mar 31, 2026MOULDER LEON O JRChief Executive OfficerAcquired · Open-market buy34,000$19.31↗
Mar 31, 2026Lu HongbodirectorAcquired · Open-market buy75,000$20.00↗
Mar 30, 2026MOULDER LEON O JRChief Executive OfficerAcquired · Open-market buy20,000$18.23↗
Feb 13, 2026Allen Patricia LdirectorAcquired · Open-market buy4,160$26.36↗

* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How much of Zenas Biopharma do institutions hold?

13F filers reported holding 31.9% of Zenas Biopharma's shares as of Sep 30, 2026, across 76 filers.

How many 13F filers hold Zenas Biopharma?

Zenas Biopharma was held by 76 13F filers as of Sep 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.